{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:32:26Z","timestamp":1792575146457,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Guangdong Provience","award":["2023A1515011525"],"award-info":[{"award-number":["2023A1515011525"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470185, 82073917"],"award-info":[{"award-number":["82470185, 82073917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sun Yat-sen University Cancer Center Clinical Research 308 Program","award":["2014-fxy-106, 2016-fxy-079"],"award-info":[{"award-number":["2014-fxy-106, 2016-fxy-079"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04080-6","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:35:32Z","timestamp":1749033332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3\u2009\u00d7\u2009CD20 bispecific antibodies for Chinese patients"],"prefix":"10.1007","volume":"74","author":[{"given":"Peng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Tian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Shuo","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"3","key":"4080_CR1","doi-asserted-by":"publisher","first-page":"e433516","DOI":"10.1200\/EDBK_433516","volume":"44","author":"A Braun","year":"2024","unstructured":"Braun A, Gouni S, Pulles A, Strati P, Minnema MC, Budde LE (2024) Bispecific antibody use in patients with lymphoma and multiple myeloma. Am Soc Clin Oncol Educ Book 44(3):e433516","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18","key":"4080_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G et al (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 39(18):1959\u20131970","journal-title":"J Clin Oncol"},{"issue":"8","key":"4080_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065","journal-title":"Lancet Oncol"},{"issue":"12","key":"4080_CR4","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H et al (2023) Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol 41(12):2238\u20132247","journal-title":"J Clin Oncol"},{"issue":"5","key":"4080_CR5","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R, Arnason JE, Advani RH et al (2022) Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 9(5):e327\u2013e339","journal-title":"Lancet Haematol"},{"issue":"9","key":"4080_CR6","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R et al (2024) A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med 30(9):2667\u20132678","journal-title":"Nat Med"},{"issue":"14","key":"4080_CR7","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.3390\/ijms22147652","volume":"22","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S (2021) Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci 22(14):7652","journal-title":"Int J Mol Sci"},{"issue":"24","key":"4080_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F et al (2022) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 387(24):2220\u20132231","journal-title":"N Engl J Med"},{"issue":"4","key":"4080_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transpl"},{"issue":"16","key":"4080_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L et al (2024) Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood 143(16):1565\u20131575","journal-title":"Blood"},{"issue":"21","key":"4080_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306","journal-title":"Blood"},{"issue":"11","key":"4080_CR12","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ajh.27056","volume":"98","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Wang Y, Albanyan O et al (2023) The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol 98(11):1699\u20131710","journal-title":"Am J Hematol"},{"issue":"5","key":"4080_CR13","doi-asserted-by":"publisher","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Perez A, Iacoboni G et al (2022) The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer 10(5):e004475","journal-title":"J Immunother Cancer"},{"issue":"24","key":"4080_CR14","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P et al (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138(24):2499\u20132513","journal-title":"Blood"},{"issue":"6","key":"4080_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679","journal-title":"Cancer Discov"},{"issue":"14","key":"4080_CR16","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","volume":"8","author":"G Gritti","year":"2024","unstructured":"Gritti G, Belousov A, Relf J, Dixon M, Tandon M, Komanduri K (2024) Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma. Blood Adv 8(14):3615\u20133618","journal-title":"Blood Adv"},{"issue":"6","key":"4080_CR17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","volume":"89","author":"LM Forrest","year":"2003","unstructured":"Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6):1028\u20131030. https:\/\/doi.org\/10.1038\/sj.bjc.6601242","journal-title":"Br J Cancer"},{"issue":"1","key":"4080_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-023-01488-4","volume":"16","author":"X Liu","year":"2023","unstructured":"Liu X, Zhao J, Guo X, Song Y (2023) CD20 \u00d7 CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol 16(1):90","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4080_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"I Hosseini","year":"2020","unstructured":"Hosseini I, Gadkar K, Stefanich E et al (2020) Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl 6(1):28","journal-title":"NPJ Syst Biol Appl"},{"issue":"1","key":"4080_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques P, Kirkwood AA, Kwon M et al (2024) Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol 17(1):61","journal-title":"J Hematol Oncol"},{"key":"4080_CR21","first-page":"39","volume":"44","author":"K Zhao","year":"2023","unstructured":"Zhao K, Sun J, He M, Ruan H, Lin G, Shen N (2023) A predictive model of severe cytokine release syndrome after coadministration of CD19- and CD22-chimeric antigen receptor T-cell therapy in children with B-cell hematological malignancies based on patient-reported outcomes. Cancer Nurs 44:39\u201344","journal-title":"Cancer Nurs"},{"issue":"1","key":"4080_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13139-009-0009-0","volume":"44","author":"XC Nguyen","year":"2010","unstructured":"Nguyen XC, Lee WW, Amin AM et al (2010) Tumor burden assessed by the maximum standardized uptake value and greatest diameter on FDG-PET predicts prognosis in untreated diffuse large B-cell lymphoma. Nucl Med Mol Imaging 44(1):39\u201344","journal-title":"Nucl Med Mol Imaging"},{"issue":"3","key":"4080_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau AS, Meignan M, Nioche C et al (2021) Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(\u2020). Ann Oncol 32(3):404\u2013411","journal-title":"Ann Oncol"},{"issue":"10","key":"4080_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00277-010-0964-7","volume":"89","author":"MK Song","year":"2010","unstructured":"Song MK, Chung JS, Sung-Yong O et al (2010) Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy. Ann Hematol 89(10):985\u2013991","journal-title":"Ann Hematol"},{"key":"4080_CR25","doi-asserted-by":"publisher","first-page":"106521","DOI":"10.1016\/j.leukres.2021.106521","volume":"102","author":"S Ba\u015fc\u0131","year":"2021","unstructured":"Ba\u015fc\u0131 S, Yi\u011feno\u011flu TN, Bak\u0131rta\u015f M et al (2021) The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor. Leuk Res 102:106521","journal-title":"Leuk Res"},{"key":"4080_CR26","doi-asserted-by":"publisher","first-page":"1063438","DOI":"10.3389\/fonc.2023.1063438","volume":"13","author":"M Ma'koseh","year":"2023","unstructured":"Ma\u2019koseh M, Farfoura H, Khatib Y et al (2023) Definition of bulky disease in early stage diffuse large B-cell lymphoma in computed tomography on coronal and transverse planes. Front Oncol 13:1063438","journal-title":"Front Oncol"},{"key":"4080_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4161\/viru.24530","volume":"4","author":"AV Page","year":"2013","unstructured":"Page AV, Liles WC (2013) Biomarkers of endothelial activation\/dysfunction in infectious diseases. Virulence 4:507\u2013516","journal-title":"Virulence"},{"key":"4080_CR28","doi-asserted-by":"publisher","first-page":"155149","DOI":"10.1016\/j.cyto.2020.155149","volume":"133","author":"L Wang","year":"2020","unstructured":"Wang L, Ruan M, Yan H, Lei B, Sun X, Chang C et al (2020) Pretreatment serum neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios: two tumor-related systemic inflammatory markers in patients with thymic epithelial tumors. Cytokine 133:155149","journal-title":"Cytokine"},{"key":"4080_CR29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/1055-9965.EPI-18-1066","volume":"28","author":"YH Choi","year":"2019","unstructured":"Choi YH, Lee JW, Lee SH, Choi JH, Kang J, Lee BS et al (2019) A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with advanced gallbladder cancer receiving chemotherapy. Cancer Epidemiol Biomark Prev 28:1045\u20131051","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4080_CR30","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/brainsci12081034","volume":"12","author":"K Dadouli","year":"2022","unstructured":"Dadouli K, Janho MB, Hatziefthimiou A, Voulgaridi I, Piaha K, Anagnostopoulos L et al (2022) Neutrophil-to-lymphocyte, monocyte-to-lymphocyte, platelet-to-lymphocyte ratio and systemic immune-inflammatory index in different states of bipolar disorder. Brain Sci 12:1034","journal-title":"Brain Sci"},{"issue":"7","key":"4080_CR31","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/jso.25414","volume":"119","author":"DC Mo","year":"2019","unstructured":"Mo DC, Liu X, Lv YJ, Qin YQ, Xie GS (2019) Is monocyte-to-lymphocyte ratio the best systematic inflammatory biomarker for the prognosis of gastrointestinal stromal tumors. J Surg Oncol 119(7):1024\u20131025. https:\/\/doi.org\/10.1002\/jso.25414","journal-title":"J Surg Oncol"},{"issue":"2","key":"4080_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5603\/rpor.100168","volume":"29","author":"H Tanaka","year":"2024","unstructured":"Tanaka H, Ono T, Kajima M, Manabe Y, Fujimoto K, Yuasa Y, Shiinoki T, Matsuo M (2024) Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy. Rep Pract Oncol Radiother 29(2):228\u2013235. https:\/\/doi.org\/10.5603\/rpor.100168","journal-title":"Rep Pract Oncol Radiother"},{"key":"4080_CR33","doi-asserted-by":"publisher","first-page":"1094378","DOI":"10.3389\/fimmu.2023.1094378","volume":"14","author":"L Zheng","year":"2023","unstructured":"Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, Zheng X, Han B, Zhong H, Nie W, Zhang X (2023) Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer. Front Immunol 14:1094378. https:\/\/doi.org\/10.3389\/fimmu.2023.1094378","journal-title":"Front Immunol"},{"key":"4080_CR34","doi-asserted-by":"publisher","first-page":"1393939","DOI":"10.3389\/fimmu.2024.1393939","volume":"15","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Ray MD, Zur RM et al (2024) Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States. Front Immunol 15:1393939","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04080-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:01:33Z","timestamp":1749938493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04080-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4080"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04080-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted with the approval of independent ethics committees or institutional review boards of all the study centers and in accordance with the principles of the Declaration of Helsinki.All patients involved in the study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}